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Abstract 
 Preeclampsia is an important cause of both fetal and maternal 
morbidity and mortality worldwide and in Sudan.  Early diagnosis and 
follow up will significantly improve the outcome of the disease. 
 Serum uric acid is widely used for diagnosis and follows up of 
preeclampsia. 
 This study is conducted to compare serum uric acid in patients 
with preeclampsia with normal control. 
Objective: 
 The objective of this study is to estimate the serum uric acid in 
preeclampsia and in normal pregnancy.  It aims also to detect if there 
is any significant difference, and to relate serum uric acid to the 
severity of the disease. 
Materials and Methods:  
 This is a case-control hospital based study covering 100 (50 
case/50 control) pregnant ladies in their third trimester in the unit of 
obstetric and gynaecology in KTH.  The study was conducted in the 
period from September 2009 to Jan 2010.   
 Clinical data was obtained from patients through questionnaire.  
Serum uric acid was analyzed in the laboratory at the same hospital. 
Results:  the mean serum uric acid of the control group was 4.47 
mg/dL. (within the normal range). 
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 The mean for the case group is 7.35 mg/dL (above the normal 
range).  P value = 0.000 statistically is highly significant. 
 Serum uric acid correlate well with the severity of disease. 
Conclusions and Recommendations: 
 Preeclampsia is associated with rise in serum uric acid level.  
The higher the blood  pressure in preeclampsia the higher the rise in 
serum uric acid level.  
It is recommended that serum uric acid   measurement is included 
in the follow up of preeclampsia.  
Serum uric acid level should be  used as a predictive factor for 
preeclampsia. 
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 ﻣﺴﺘﺨﻠﺺ اﻟﺒﺤﺚ
 
ﺳﺒﺒًﺎ هﺎﻣًﺎ ﻻﻋﺎﻗﺔ ووﻓﻴﺎت اﻟﻤﻮاﻟﻴﺪ واﻻﻣﻬﺎت ﻋﺒﺮ اﻟﻌﺎﻟﻢ وﻓﻲ ( آﻠﺒﺶ) اﻻرﺟﺎج ﺗﻌﺘﺒﺮ ﻣﻘﺪﻣﺔ 
  .اﻟﺴﻮدان ، اﻟﺘﺸﺨﻴﺺ اﻟﻤﺒﻜﺮ وﻣﺘﺎﺑﻌﺔ اﻟﺤﺎﻻت ﺗﺴﺎهﻢ ﺑﺼﻮرة ﻣﻠﺤﻮﻇﺔ ﻓﻲ ﺗﺤﺴﻴﻦ اﻟﻨﺘﺎﺋﺞ 
اﻟﻴﻮرﻳﻚ ﻓﻲ ﻣﺼﻞ اﻟﺪم ﻣﻦ اﻟﻔﺤﻮﺻﺎت اﻟﻤﺨﺘﺒﺮﻳﺔ اﻟﻬﺎﻣﺔ ﻓﻲ ﺗﺸﺨﻴﺺ ﻳﻌﺘﺒﺮ ﻗﻴﺎس ﺣﻤﺾ 
  .وﻣﺘﺎﺑﻌﺔ اﻟﻤﺮض
 ﺗﻬﺪف هﺬﻩ اﻟﺪرﺳﺎة ﻟﻤﻘﺎرﻧﺔ ﻣﺴﺘﻮي ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻓﻲ اﻟﻤﺼﻞ ﺑﻴﻦ ﻧﺴﺎء ﻣﺼﺎﺑﺎت ﺑﻤﻘﺪﻣﺔ 
  .ﺳﻠﻴﻤﺎت ﻓﻲ اﻟﺴﻮدانﺣﻮاﻣﻞ  وﺁﺧﺮ (اﻟﻜﻠﺒﺶ) اﻻرﺟﺎج
  :اﻻهﺪاف
ﺪم ﻓﻲ ﺣﺎﻟﺔ اﻟﺤﻤﻞ اﻟﺴﻠﻴﻢ ﺗﻬﺪف هﺬﻩ اﻟﺪراﺳﺔ ﻟﻤﻌﺮﻓﺔ ﻣﺴﺘﻮي ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻓﻲ ﻣﺼﻞ اﻟ
وﻣﻌﺮﻓﺔ ﻣﺴﺘﻮاﻩ ﻓﻲ ﻣﺼﻞ اﻟﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت ، وﺗﻬﺪف اﻳﻀًﺎ ﻟﻤﻌﺮﻓﺔ اذا ﻣﺎ آﺎن هﻨﺎك ﻋﻼﻗﺔ ﺑﻴﻦ 
  .ارﺗﻔﺎع ﻣﺴﺘﻮي اﻟﺤﻤﺾ ﻓﻲ اﻟﺪم ودرﺟﺔ اﺷﺘﺪاد اﻟﻤﺮض 
  :اﻟﻤﻮاد واﻟﻮﺳﺎﺋﻞ
اﺟﺮﻳﺖ ﻋﻠﻲ ﻧﺴﺎء . ﺗﻤﺖ هﺬﻩ اﻟﺪراﺳﺔ ﺑﺎﻟﻤﺴﺘﺸﻔﻲ ﺑﻤﻘﺎرﻧﺔ ﻋﻴﻨﺎت اﻟﻤﺮﺿﻲ ﺑﻌﻴﻨﺎت ﺿﺎﺑﻄﺔ 
  .ﻠﺚ اﻻﺧﻴﺮ ﻟﻠﺤﻤﻞ ﺑﻘﺴﻢ اﻟﻨﺴﺎء واﻟﺘﻮﻟﻴﺪ ﺑﻤﺴﺘﺸﻔﻲ اﻟﺨﺮﻃﻮم اﻟﺘﻌﻠﻴﻤﻲ ﻓﻲ اﻟﺜ
ﺗﻢ ﺟﻤﻊ اﻟﻤﻌﻠﻮﻣﺎت اﻟﺴﺮﻳﺮﻳﺔ ( . ﻋﻴﻨﺔ ﺿﺎﺑﻄﺔ 05ﻋﻴﻨﺔ ﻣﺼﺎﺑﺔ و  05)ﺳﻴﺪة  001ﺗﻀﻤﻨﺖ اﻟﺪراﺳﺔ 
ﻣﻦ اﻟﻨﺴﺎء ﺑﻮاﺳﻄﺔ اﻻﺳﺘﺒﻴﺎن ، ﺗﻢ ﺗﺤﻠﻴﻞ ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻓﻲ ﻣﺼﻞ اﻟﺪم ﻓﻲ وﺣﺪة اﻻﺑﺤﺎث واﻟﻤﻌﺎﻣﻞ 
  .ﻓﻲ ذات اﻟﻤﺴﺘﺸﻔﻲ 
  :اﻟﻨﺘﺎﺋﺞ
اﻟﻌﻴﻨﺔ )ﺗﻮﺻﻠﺖ اﻟﺪراﺳﺔ اﻟﻲ ان ﻣﺘﻮﺳﻂ ﻣﺴﺘﻮي ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻓﻲ ﻣﺼﻞ اﻟﻨﺴﺎء اﻟﺴﻠﻴﻤﺎت 
 53.7دس وﻳﻌﺘﺒﺮ هﺬا ﺿﻤﻦ اﻟﻤﻌﺪل اﻟﻄﺒﻴﻌﻲ ، وﻓﻲ اﻟﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت /ﻣﻠﺠﻢ  74.4( اﻟﻀﺎﺑﻄﺔ
. دس وهﻲ اﻋﻠﻲ ﻣﻦ اﻟﻤﻌﺪل اﻟﻄﺒﻴﻌﻲ وﺑﺎﻟﺘﺎﻟﻲ ﻳﺘﻤﻴﺰ اﻟﻤﺮض ﺑﺎرﺗﻔﺎع ﻣﺴﺘﻮي اﻟﺤﻤﺾ ﻓﻲ اﻟﺪم /ﻣﻠﺠﻢ
ﺖ اﻟﺪراﺳﺔ اﻟﻲ اﻧﻪ آﻠﻤﺎ ازدادت ﺷﺪة اﻟﻤﺮض زاد ﻣﻌﺪل ارﺗﻔﺎع اﻟﺤﻤﺾ ﻓﻲ اﻟﻤﺼﻞ وﺑﺎﻟﺘﺎﻟﻲ وﺗﻮﺻﻠ
  .ﻳﻌﺘﺒﺮ ارﺗﻔﺎع اﻟﺤﻤﺾ دﻟﻴًﻼ ﻋﻠﻲ وﺧﺎﻣﺔ اﻟﻤﺮض
 
  :اﻟﺨﻼﺻﺔ واﻟﺘﻮﺻﻴﺎت
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، ﺗﻮﺻﻲ  (اﻟﻜﻠﺒﺶ) اﻻرﺟﺎجﻳﻌﺘﺒﺮ ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻣﻦ اﻟﻤﻮﺳﻤﺎت اﻟﻬﺎﻣﺔ ﻟﻤﺮض ﻣﻘﺪﻣﺔ 
ﻮﺻﻲ اﻟﺪراﺳﺔ ﺑﺎﺳﺘﻌﻤﺎل ﺣﻤﺾ اﻟﻴﻮرﻳﻚ ﻓﻲ اﻟﻤﺴﻮﺣﺎت آﻤﺎ ﺗ. اﻟﺪراﺳﺔ ﺑﺎﺳﺘﻌﻤﺎﻟﻪ ﻓﻲ ﻣﺘﺎﺑﻌﺔ اﻟﻤﺮض 
  . ﻟﻼﺧﺘﻴﺎر اﻟﻤﺒﻜﺮ ﻟﻠﺤﺎﻻت اﻟﻤﻌﺮﺿﺔ ﻟﻼﺻﺎﺑﺔ ﺑﺎﻟﻤﺮض
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CHAPTER ONE 
1- INTRODUCTION AND LITERATURE REVIEW 
1.1. INTRODUCTION  
Preeclampsia, a special entity of hypertensive 
disorders of pregnancy, is a syndrome of reduced organ 
perfusion secondary to vasospasm and endothelial 
dysfunction.(1)  
Preeclampsia is diagnosed  on the basis of high blood 
pressure,  oedema and proteinuria, other clinical features as 
headache, epigastric pain support the diagnosis, a further 
support, to the diagnosis is given by chemical markers of 
organ and system dysfunction such as elevated levels of 
serum urea and creatinine, liver enzymes and uric acid.(1)  
Preeclampsia is an important cause of both fetal and 
maternal morbidity and mortality complicating up to 5% of 
pregnancies. In developed countries as UK where prenatal 
care is a routine it accounts for 15% of preterm deliveries. 
Worldwide in settings without good prenatal care as in West 
Africa preeclampsia increases the risk of fetal death five-
folds and kills 50,000 women a year.(2) 
2 
 
The only treatment of preeclampsia is delivery of the 
fetus and placenta.(1) The difficult decision whether to end 
pregnancy to save a mother with a preterm baby that is not 
ready for extrauterine life or to continue pregnancy to give a 
fetus the benefit of time, but still serious complications for 
fetus and mother are present. Here comes the role of clinical 
chemistry laboratory to give accurate results of markers of 
the severity of the disease along with proper clinical 
assessment.  
The utility of uric acid in preeclampsia is being 
studied intensively worldwide: Its use as a marker of severity 
or as a pathogenic factor or its predictive value are widely 
used.  
 
 
 
 
 
 
3 
 
1.2. LITERATURE REVIEW 
 1.2.1. Physiological and chemical changes in normal 
pregnancy: 
Pregnancy encompasses the period from conception to 
birth. During this period the pregnant woman experience 
major physical, chemical and psychological changes that 
support maternal adaptations and fetal growth and 
development as well as prepare the mother for the birth 
process and transition to parenthood.(3)  
Most of the changes encountered during pregnancy 
are progressive and can be attributed to either the very high 
circulating concentrations of hormones, e.g. estrogens and 
progesterone that affect many organs and alter the 
concentrations of many substances In plasma e.g. carrier 
proteins or physiological changes of maternal organ systems 
so as to adapt for the increase demand posed by the 
requirements of the growing fetus, e.g. changes in 
cardiovascular and respiratory systems.(4)   
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1.2.1.1. Volume homeostasis: 
One of the most fundamental systemic changes of 
normal pregnancy is fluid retention which accounts for 8-10 
kg of the average maternal weight gain of 11-13 kg.(5) Fluid 
retention mainly affects   plasma volume. This is due to a 
series of other physiological adaptations notably the increase 
in cardiac output and in renal blood flow.  
The factors contributing to fluid retention are: sodium 
retention; the marked increase in concentrations of anti-
natriuretic hormones such as  aldosterone and the 20% 
decrease in plasma oncotic pressure.   The consequences of 
fluid retention are reducation in haemoglobin concentration, 
haematocrit and serum albumin concentration, while stroke 
volume and renal blood flow increase. (5)  
1.2.1.2. Blood: 
Pregnant women undergo an average increase of 
about 1250 ml of plasma volume which represents 50% 
increase. Red cell mass also increases but the rise is 
influenced by iron supplementation: rise up to 30% in 
women taking iron supplements and 18% in the absence of 
5 
 
iron.  But as red cell mass increases by a smaller amount 
than plasma volume, a fall in haematocrit and haemoglobin 
concentrations  the so-called physiologic anaemia occurs in 
normal pregnancy.(6) 
An increase in the peripheral white cell count 
normally occurs in pregnancy with a mean of 9500/mm3, 
this is due to increase in neutrophil count which returns to 
normal 6 weeks postpartum. Eosinophils, lymphocytes and 
monocytes remain normal. Platelets count drops with a 
mean of 260.000/mm3.  Circulating levels of coagulation 
factors VII, X and fibrinogen show dramatic increase, factor 
II, V & VIII remain unchanged while factors XI and XIII 
decrease.(6) 
 Pregnancy is considered as a hypercoagulable state, 
which is useful at the time of placental separation.  At term, 
about 550 ml of blood flows through the placental bed per 
minute.  Without effective and rapid haemostasis a woman 
could die from bleeding within a few minutes.  The 
myometrium contraction is the first line of defense 
compressing the blood vessels supplying the placental bed.  
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The disadvantage of this hypercoagulable state is the 
increased risk of thrombosis and thromboembolism(5). 
1.2.1.3. Cardiovascular Changes: 
When plasma volume expands following fluid 
retention both heart rate and stroke volume increase by 10-
20% and 10% respectively, resulting in increase of 30-50% of 
cardiac output from 5 L/min before pregnancy  to 7 L/min.(5) 
Despite the increase in circulating plasma volume and 
cardiac output, the greater part of normal pregnancy is 
characterized by a reduction in arterial blood pressure.(6) 
The decrease in peripheral vascular resistance is a 
major feature of a normal pregnancy, many factors are 
involved but it seems that the predominance of vasodilator 
factors e.g., progresterone and prostaglandins over 
vasoconstrictor factors and the presence of uteroplacental 
circulation which functions as a physiologic shut are the 
most important. (6) 
1.2.1.4. Respiratory system: 
Pulmonary blood flow increases as a result of the 
increase in cardiac output. Tidal volume increases so the 
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lungs function more effectively, facilitating gas transfer, as a 
consequence, there is drop (15-20%) of PCO2, and increase 
in PO2.  During pregnancy there is an increase in 2,3 
disphosphoglycerate (2.3 DPG) concentrations within 
maternal erythrocytes  which promotes the release of oxygen 
from the red cell at lower levels of haemoglobin saturation so 
both tissues and fetus get maximum oxygen benefit.(6) 
Dyspnoea a common symptom of pregnancy seems to result 
from increased tidal volume rather than increase in 
respiratory rate(3).   
1.2.1.5. The Urinary tract and renal function: 
During pregnancy kidneys enlarge up to 70% due to 
increase in both the interstitial space and intravascular 
volume, dilatation of ureters, and calicies also occur this is 
explained by the relaxant effect of progesterone.  By the third 
trimester 97% of women show evidence of stasis or 
hydronephrosis which contributes to urinary tract 
infection.(5)  The renal blood flow increases by 60-75%, which 
leads to increase in glomerular filtration rate by 50%.  
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The increase in glomerular filtration rate itself is 
responsible for the increase in the clearance of a number of 
substanbces from the blood stream, so plasma levels of 
these substances reduce, e.g., blood urea nitrogen, serum 
creatinine and serum uric acid.  There is an increase in total 
protein excretion to 0.3 grams/day in normal pregnancy.(5)  
Glycosuria is common in pregnancy due to increase in 
Glomerular filtration rate and decrease in reabsorbtion 
mechanisms in proximal renal tubules.(6) 
1.2.1.6. The digestive system and liver: 
Pregnancy is characterized by decreased gastric 
motility and decreased gastric secretion consistent with the 
infrequency of peptic ulcer disease and improvement in pre-
existing ulcer symptoms. Increased mucus production in 
response to estrogen and progesterone may also be involved 
in improving peptic ulcer disease in pregnancy.(6)  
Small intestines show decrease in motility and 
enhanced absorption of calcium and iron.  Large intestines 
changes during pregnancy are associated with decreased 
motility and enhanced water and sodium absorption both 
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factors contribute to constipation encountered by many 
pregnant women.(6) 
Liver function changes include a 30% fall in albumin, 
two to four folds rise in alkaline phosphatase due to 
placental iso-enzyme. The occasional spider angiomata and 
palmer erythema are attributed to increased estrogen levels. 
Aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), bilirubin and prothrobin time remain unchanged λ-
glutamyl transpeptidase GGT levels show variable changes.(4) 
1.2.1.7. Endocrinological changes: 
Many of the peptides and steroid hormones produced 
by the endocrine glands in the non-pregnant state are also 
produced by intrauterine tissues during pregnancy.  
Human chorionic gonadotrophin (hCG) is produced by 
trophoblastic cells and is detectable within the maternal 
circulation in small quantities within days of implantation, it 
has a major role during early pregnancy in maintaining the 
function of the corpus luteum, as placental production of 
progesterone predominate later in first trimester hCG levels 
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decline.(7)  hCG also suppresses the secretion of both FSH 
and LH. (6)   
Both estrogens and progesterone have effects upon 
the myometrium (oestrogen encourages cellular hypertrophy, 
whereas progesterone discourages contraction) together with 
prolactin they affect breast tissues. It is likely that they exert 
effects on many other target tissues during pregnancy such 
as smooth muscles of the vascular tree and the urinary and 
gastrointestinal tracts.(5) 
An insulin-resistant condition similar to that of type II 
diabetes accompanies normal pregnancy, human placental 
lactogen hPL, prolactin, cortisol, estrogen and progesterone 
are all responsible for this hyperglycaemia.(6) 
As the synthesis of thyroxin binding globulin 
increases (TBG) serum levels of total T3 and T4 also 
increase.(6)  
About 40% of calcium is bound to albumin and as 
albumin concentrations decrease during pregnancy, total 
plasma calcium also decreases. As fetus needs calcium 
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maternal absorption of calcium increases and excretion 
decreases.(5) 
ACTH levels remain within the normal range 
glucocorticoids increase since plasma cortisol binding 
globulin CBG concentrations increase.   Circulating 
concentration of the anti-natriuretic hormones aldosterone 
and deoxycorticosterone increase up to ten-folds.(5) 
1.2.1.8. Plasma lipids: 
Plasma trigelyceride, cholesterol, low-density 
lipoprotein (LDL) and high density lipoprotein (HDL) are all 
increased.(7) 
1.2.2. Hypertensive Disorders Complicating Pregnancy: 
1.2.2.1. Overview: 
Hypertensive disorders complicating pregnancy are 
common and form one of the deadly triad, along with 
hemorrhage and infection, that result in much of the 
maternal morbidity and mortality related to pregnancy.(8) 
Pregnancy- induced hypertension (PIH) occurs in a 
round 16 – 24% of first pregnancies and 12 – 15% of 
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subsequent pregnancies. Pre-eclampsia complicates 3-5% of 
first pregnancies and 1% of subsequent pregnancies.(8) 
Preeclampsia accounts for around 16% of maternal deaths. 
Mortality from hypertensive disorders is much higher in 
developing countries reaching rates of 70 -120 per 100,000. 
Of maternal deaths in the United Kingdom 40% are 
associated with eclampsia. Overall perinatal mortality in pre-
eclampsia is around 35 per 1000 total births but may reach 
160 per 1000 in severe disease. The most important factor 
determining outcome is gestational age at delivery; survival 
being < 40% when delivery is indicated before 28 weeks 
gestation for gestational age (SGA), perinatal mortality is not 
increased in PIH.(8)  
The term pregnancy induced hypertension was and is 
still widely used to describe any new-onset pregnancy-
related hypertension, it was intended to include 
hypertension without proteinuria, yet it is a potential 
precursor to preeclampsia or eclampsia which requires 
proteinuria for diagnosis. (7)  
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Recently, the working group of the National High 
Blood Pressure Education Program (2000) USA has proposed                    
a classification system that will help to deal with all the non-
uniform and confusing terminology that has long plagued 
the diagnosis of hypertension in pregnancy.(1) 
1.2.2.2. Diagnosis and classification:    
1- Gestational hypertension: 
- Blood pressure ≥140/90 mmHg for first time during 
pregnancy. 
- No proteinuria.  
- Blood pressure return to normal <12 weeks 
postpartum.  
- Final diagnosis made only postpartum.  
- May have other signs of preeclampsia, example 
epigastric discomfort or thrombocytopenia.   
2- Preeclampsia: 
Minimum criteria: 
- Blood pressure ≥140/90 mmHg after 20 weeks 
gestation. Proteinuria ≥ 300 mg/24 hours or ≥ 1+ 
dipstick.   
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 Increased certainty of preeclampsia: 
- Blood pressure ≥ 160/110 mmHg.  
- Proteinuria 2.0 g/24 hours or ≥ 2 + dipstick.  
- Serum creatinine > 1.2 mmg/dl unless known to be 
previously elevated.  
- Platelets < 100,000 mm3.  
- Microangiopathic hemolysis  that causes increased 
LDH .  
- Elevated ALT or AST.  
- Persistent headache or other cerebral or visual 
disturbances.  
- Persistent epigastric pain.  
3- Eclampsia: Seizure that can not be attributed to other 
causes in a woman with pre-eclampsia.  
4- Superimposed preeclampsia (on chronic 
hypertension):  
New-onset proteinuria ≥300 mg/24 hours in 
hypertensive women, but no proteinuria before 20 weeks 
gestation.  
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A sudden increase in proteinuria or blood pressure or 
platelets count <100,000 mm3 in women with hypertension 
and proteinuria before 20 weeks gestation.  
5- Chronic hypertension:  
Blood pressure ≥140/90 mmHg before pregnancy or 
diagnosed before 20 weeks gestation. Hypertension first 
diagnosed after 20 weeks gestation and persists after 12 
weeks postpartum.(1) 
1.2.3. Preeclampsia:  
1.2.3.1. Definition:  
Preeclampsia is a pregnancy-specific syndrome of 
reduced organ perfusion secondary to vasospasm and 
endothelial activation. Proteinuria is an important sign of 
preeclampsia the diagnosis is questionable in its absence; 
proteinuria is described as 300 mg or more of urinary 
protein per 24 hours or persistent 30 mg/dl (1 dipstick) in 
random urine samples. The degree of proteinuria may 
fluctuate widely over any 24 hour period, even in severe 
cases. Therefore a single random sample may fail to 
demonstrate significant proteinuria.  The more severe the 
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hypertension and proteinuria the more certain the diagnosis 
of preeclampsia.(1)   
1.2.3.2. Diagnostic feature of preeclampsia:  
In addition to hypertension and proteinuria other 
diagnostic features include: headache, visual disturbances, 
upper-abdominal pain oliguria, convulsions, elevated serum 
creatinine, thrombocytopenia liver enzyme elevation, fetal 
growth restriction and pulmonary oedema. (1) 
1.2.3.3. Etiology and risk factors:  
In 1916 pre-eclampsia was called the disease of 
theories almost a century later; this characterization is still 
accurate. Despite extensive research, the cause of 
preeclampsia remains uncertain. There are however, well-
recognized predisposing factors as primigravid status, family 
history of preeclampsia or eclampsia, new paternity 
,extremes of maternal age (younger than 20 or older than 35 
years of age).(9) Pre-existing hypertensive, vascular, 
autoimmune or renal disease, diabetes mellitus, multiple 
gestation,nonimmun or alloimune fetal hydrops,hydatidiform 
mole and obesity.(9) 
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Data support contribution from several areas in the 
pathogenesis of the disease: immunogenetic factors, 
increased vascular reactivity and endothelial injury, 
coagulation abnormalities, oxygen free radicals and lipid 
peroxidation, abnormalities of cytotophblastic differentiation 
and invasion.(9)  
1.2.3.4. Pathology of pre-eclampsia:  
Pathological deterioration of function in a number of 
organs and systems, presumably as a consequence of 
vasospasm and ischaemia, has been identified in severe 
preeclampsia and eclampsia. The major cause of fetal 
compromise occurs as a consequence of reduced 
uteroplacental perfusion.(1)  
Cardiovascular changes are basically related to 
increased cardiac afterload caused by hypertension, 
hypervolaemia of pregnancy, or iatrogenically by excessive 
intravenous fluids, and endothelial activation with 
extravasation into the extracellular space, especially the 
lungs.(1) 
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With clinical pre-eclampsia, there is a marked 
reduction in cardiac output and increased peripheral 
resistance.(1)  
Hemoconcentration is a hallmark of severe 
preeclampsia and eclampsia. In the late weeks of a normal 
pregnancy a woman should have a blood volume of nearly 
5000 ml compared with about 3500 ml with pre-eclampsia. 
This is likely a consequence of generalized vasoconstriction 
made worse by increased vascular permeability.(1)  
Some degree of intravascular coagulation is commonly 
found with pre-eclampsia. (1)   
The thrombocytopenia   is  due to  platelet activation 
and consumption. Its  clinical significance is that it reflects 
the severity of the pathological process in general, the lower 
the platelet count the greater are maternal and fetal 
morbidity and mortality.(1)  
Thrombocytopenia  may be accompanied by evidence 
of erythrocyte destruction characterized by hemolysis, 
schizocytosis, spherocytosis, reticulocytosis, hemoglobinuria 
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and occasionally hemoglobinaemia. These derangements 
result in part from microangipathic hemolysis.(1)  
Plasma levels of rennin, angiotensin II and 
aldosterone are increased during normal pregnancy, 
preeclampsia results in a decrease of these hormones toward 
the normal non-pregnant range.  The potent 
mineralocorticoid deoxycorticosteron (DOC) is increased 
strikingly in third trimester plasma, it is not reduced by 
sodium retention or hypertension, this explains why women 
with preeclampsia retain sodium.  Vasopressin levels are 
normal despite decreased plasma osmolality. Atrial 
natriuretic peptide is further increased in preeclampsia. (1) 
Commonly, the volume of extracellular fluid; 
manifested as edema, in women with severe preeclampsia 
has expanded beyond the normally increased volume that 
characterizes pregnancy. The mechanisms responsible for 
the pathological expansion is not clear, endothelial injury 
reduces plasma oncotic pressure displacing intravascular 
fluid into the surrounding interstitium.  Electrolyte 
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concentrations do not differ appreciably in women with 
preeclampsia compared with those of normal pregnancy.(1)  
During normal pregnancy, renal blood flow and 
glomerular filtration rate (GFR) increase. Levels that are 
much below normal non-pregnant values are the 
consequences of severe preeclambpsia. Plasma uric acid 
concentrations are typically elevated especially in women 
with more severe diseases.  
In the majority of preeclamptic women GFR, diminished   
leading to creatinine values twice these of normal pregnancy. 
In some cases, renal involvement is profound and plasma 
creatinine may be highly elevated.(1)   
There should be some degree of proteinuria to establish 
the diagnosis of preeclampsia, 24-hour urine excretion 
should be measured. It was found that urinary dipstick of 1 
+ proteinuria or greater was predictive of at least 300 mg per 
24 hours in 92% of cases.  
Albuminuria is an incorrect term to describe 
proteinuria of preeclampsia, as with any other 
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glomerulopathy there is increased permeability to most 
large-molecular-weight proteins.(1) 
Liver involvement in preeclampsia- eclampsia is serious 
and is frequently accompanied by evidence of other organ 
involvement. This is commonly referred to as HELLP 
syndrome (Hemolysis Elevated Liver Enzymes and Low 
Platelets). Some studies stated that up to 20% of women 
with severe preeclampsia and eclampsia develop HELLP 
syndrome.(1)  
Central nervous system manifestations of preeclampsia 
and especially the convulsions of eclampsia have been long 
known. In particular visual symptoms have received much 
attention. The earliest descriptions of brain involvement 
came from gross and histological examination, but with 
modern non-invasive techniques, imaging and Doppler 
studies have added new insight into cerebrovascular 
involvement.(1)  
The principal postmortem cerebral lesions of severe 
preeclampsia and eclampsia are edema, hyperemia, focal 
anaemia, thrombosis and hemorrhage.(1)  
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  The most common abnormalities detected by CT 
scan are hypodense areas in cerebral cortex which 
corresponded to the petechial hemorrhages and infarction 
sites. (1)  
Visual disturbances is caused by retinal artery 
vasospasm or retinal detachment.(1)  
Central nervous system manifestations from more 
widespread cerebral edema are worrisome. In some cases 
confusion is the major feature. In a few cases overt coma 
develops. Brain stem herniation is a serious complication for 
coma patients.(1)  
Transcranial Doppler ultrasonography showed 
increased cerebral perfusion pressure counterbalanced by 
increased cerebrovascular resistance with no net change in 
cerebral blood flow.(1) 
Compromised placental perfusion from vasospasm is 
the major factor in the genesis of increased perinatal 
morbidity and mortality associated with preeclampsia. A 
study reported that the mean diameter of myometrial spinal 
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arterioles of normal pregnant women was 500 mm compared 
to 200 mm in preeclampsia.(1)  
Classically in normal pregnancy, spinal arteries are 
invaded by endovascular trophoblasts. It seems that in 
preeclampsia decidual vessels but not myometrial vessels 
are invaded by endovascular trophoblasts. Electron 
microscopy studies of arteries taken from the uteroplacental 
implantation site reported endothelial damage, insudation of 
plasma constituents into vessel walls, proliferation of 
myointimal cells and medical necrosis. The magnitude of 
defective trophoblastic invasion of the spiral arteries 
correlates with the severity of preeclampsia.(1)  
1.2.3.5. Pathophysiology of preeclampsia: 
20% to 25% of maternal cardiac output supply the 
uterus and the intervillous space (IVS), allowing exchange of 
materials between maternal and fetal circulation.(3)  
Overall the pressure within this system is low due to 
anatomic changes in maternal uterine blood vessels. These 
changes are mediated by extravillous invasive trophoblasts 
that invade the spiral arteries in the deciduas and upper 
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third of the myometrium replacing  spiral artery endothelium 
by a fibrinoid extracellular matrix and destroying muscular 
and elastic elements in the medial tissue.  As  a result the 
spiral arteries (now called uteroplacental arteries) become 
sac like structures unresponsive to maternal 
vasoconstrictive agents and able to accommodate the blood 
needed to supply the IVS.(3) 
Switching from a proliferative function to an invasive 
function is essential for normal trophoplastic function, this 
switch is abnormal  in preeclampsia.  
The extravillous invasive trophoblasts migrate into the 
maternal tissue in two waves. During the initial wave (at 6 to 
10 weeks), spiral arteries in the deciduas are altered, during 
the second wave (at 14 to 16 weeks), spiral arteries in the 
myometrium are altered. In preeclampsia the first invasive 
wave proceeds normally but there is failure of the second 
wave.(1)  
Several observations support the immunogenetic 
hypothesis: The higher rate in first pregnancies and lower 
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rates subsequently.  The rate of preeclampsia is increased in 
pregnancies conceived by a new partner. 
Maternal tissues are in direct contact with two 
trophoblastic tissues: syncytiotrophoblast and extravillous 
cytotrophoblast, in term of antigenicity both are remarkably 
inert, containing no classic major histocompatibility (MHC) 
antigens, extravillous cytotrophoblast does, however, carry    
a nonclassical truncated MHC/class (1b) antigen known as 
HLA-G. 
Studies suggest that one of the primary functions of 
HLA-G is inhibition of natural killer cell activity; this would 
serve to promote trophoblast survival.  Some investigators 
have found that trophoblastic cells from women with 
preeclampsia fail to express HLA-G mRNA or protein or have 
attenuated expression of HLA-G.(9) 
A familial predisposition to preeclampsia is well 
established and may operate as a single gene recessive trait.  
Maternal genotype alone has been implicated because of the 
increased frequency of preeclampsia in the mothers, 
daughters and granddaughters of women who have a history 
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of eclampsia.  Another group found that a molecular variant 
of the angiotensinogen gene (T235) known to be associated 
with essential hypertension, is also associated with 
preeclampsia. (1,9) 
An autoimmune connection to preeclampsia also is 
also suspected, as Antiphospholipid syndrome, is associated 
with particularly high rates of preeclampsia.(1,9) 
The underlying abnormality in preeclampsia involves 
increased vascular sensitivity to pressor hormones and 
eicosanoids and general arterial constriction.  In turn, 
increased vasoconstriction results in increased blood flow 
resistance and arterial hypertension.(1,9) 
Much investigation has focused on a role for 
vasoactive eicosanoids. Preeclampsia is marked by deficient 
prostacyclin (PGI2) activity and thromboxane A2 (TXA2) 
dominance.  Prostacyclin is a potent vasodilator and 
inhibitor of platelet aggregation.  Thromboxane A2 is a 
potent vasoconstrictor and promoter of platelet 
aggregation.(1,3,8,9) 
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Candidate circulating factors that damage or activate 
the endothelium include tumor necrosis factor- (TNF-) 
interleukin-1 (IL-1), endothelin, endothelial growth factor 
and platelet derived growth factor (PDGF). All these factors 
are high in sera of preeclamptic woman. (1,3,9)  
Coagulopathy may be one of the primary events in the 
disease. Thrombocytopenia, increased levels of thrombin-
antithrombin III complexes, decreased levels of protein C and 
antithrobmin III and increased levels of fibrin degradation 
products support the coagulopathy theory. (1,9) 
Some investigators believe that increased or 
dysregulated generation of oxygen free radicals with 
resultant plasma lipid peroxidation may be the underlying 
cause of endothelial damage and abnormal placental 
vascularization in preeclampsia.(1,9) 
1.2.3.6. Prediction of preeclampsia: 
A variety of biochemical and biophysical markers, 
based primarily on rationale implicated in the pathology and 
pathophysiology of preeclampsia, have been proposed for the 
purpose of prediction.  Investigators have attempted to 
28 
 
identify early markers of faulty placentation, reduced 
placental perfusion, endothelium cell dysfunction and 
activation of coagulation, all these attempts have resulted in 
testing strategies with low sensitivity for the prediction.(1,9)   
Angiotensin II is infused in a stepwise fashion until 
there is  20 mmHg rise in diastolic blood pressure.  Women 
requiring less than 8 mg/kg/min of angiotensin II have a 
positive-predictive value of developing preeclampsia of 20 
to40 percent.  This is quite good when compared with other 
tests for prediction.(1) 
Elevated uric acid levels in maternal blood, 
presumably due to decreased renal urate excretion, is 
frequently found in women with preeclampsia. Studies using 
uric acid measurement as a predictive factor gave variable 
results.(1) 
Alterations in calcium metabolism as well as 
deficiencies in dietary intake of calcium have been 
implicated in the pathophysiology of preeclampsia.  
Hypocalciuria has been identified with preeclampsia, several 
investigators performed studies to determine if mid 
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pregnancy urinary calcium levels might predict the 
development of preeclampsia, some studies showed good 
results.(1)  
Thrombocytopenia and abnormalities of platelets 
function may be markers for impending preeclampsia. (1,2) 
Increased levels of lipid peroxides coupled with 
decreased activity of anti-oxidants in women with 
preeclampsia has raised the possibility that markers of 
oxidative stress might be useful in the prediction possible 
markers include malondialdehyde lipid peroxidation iron and 
homocysteine.(9) 
Several cytokines, eg.  IL-1 and TNF- are of interest 
as possible markers for the development of preeclampsia.(1) 
1.2.3.7. Prevention: 
A variety of strategies have been used in attempt to 
prevent preeclampsia.  Usually these strategies involve 
manipulation of diet and pharmacological attempts to modify 
the pathophysiological mechanisms thought to be 
responsible for the disease.(1) 
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Dietary manipulations involve salt restriction, calcium 
supplementation, and fish oil capsules. (1) 
Encouraging results were obtained when low dose 
aspirin was given to pregnant ladies at risk of preeclampsia, 
this was attributed to selective suppression of thromboxane 
synthesis.  Sera of women with preeclampsia have markedly 
reduced antioxidant activity.  Studies giving antioxidants as 
vitamin E to women at risk, showed reduced endothelial cell 
activation suggesting that such therapy might be beneficial 
in the prevention of the disease.(1) 
1.2.3.8.  Management of preeclampsia: 
The most effective therapy for preeclampsia is delivery 
of the fetus and placenta.(1,5,8,9)  Therefore in pregnancies at 
or near term in which the cervix is favorable, labour should 
be induced.  Preeclampsia remote from term presents a 
much more difficult problem. 
Patients with mild preeclampsia are not candidate for 
delivery if the fetus is immature or the cervix is unfavorable 
for induction.  Successful management usually consisting of 
rest and observation.  The goals of therapy in this situation 
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are to monitor maternal and fetal parameters while allowing 
time for the fetus to mature and the cervix to ripen. 
     Delivery is always appropriate therapy for the mother 
with severe preeclampsia but may pose significant risks to 
the premature fetus especially for gestational age less than 
32 weeks.  Maternal morbidity and mortality associated with 
severe preeclampsia result principally from severe 
hypertension, eclampsia and the HELLP syndrome.  The goal 
is to lower the blood pressure to a mildly hypertensive level 
(diastolic pressure between 90 and 100 mmHg).(1,9) 
Hydralazine is the preferred agent because of its 
effectiveness and safety. (1,9)  
Eclampsia seizures are a dreaded complication 
because they are associated with unacceptably high 
mortality and morbidity rates.   Magnesium sulfate the drug 
of choice for the prevention of eclampsia. It is recommended 
that all preeclampsia women even those with mild disease 
be treated with magnesium sulfate for seizure prophylaxis 
during labour and for the first 24 hours post partum. 
Delivery of the baby and placenta is the absolute treatment. 
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Induction of labour is established as soon as it is safe.  
Nevertheless delivery by cesarean section is the common 
practice.(9) 
1.2.3.9. Prognosis: 
Preeclampsia resolves promptly after the delivery of 
the fetus and placenta. . Hypertension occasionally remains 
severe and difficult to control after delivery.  In this situation 
methyledopa or any agent can be used, the blood pressure is 
monitored every week to make sure that the hypertension 
does not persist. (9) 
In primigravidas with mild form of preeclampsia, the 
disease usually doesn’t recur in subsequent pregnancies.  
With severe preeclampsia the recurrence rate is 30% to 50%.  
Most multiparus women who have had preeclampsia or 
eclampsia on top of chronic hypertension have a 70% 
recurrence rate.(9)  
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1.2.4. Uric acid tests:  
1.2.4.1. Definition:  
Uric acid tests are tests that are done to measure the 
level of uric acid in blood serum or in urine.(10)  
 1.2.4.2. Purpose:  
The uric acid tests are used to evaluate the blood 
levels of uric acid for gout and to assess uric acid levels in 
the urine for kidney stone formation. The urine test is used 
most often to monitor patients already diagnosed with 
kidney stones, but it can also be used to detect disorders 
that affect the body's production of uric acid and to help 
measure the level of kidney functioning. 
Uric acid is a waste product that results from the 
breakdown of purine, a nucleic acid (nucleic acids are the 
building blocks of DNA.) Uric acid is made in the liver and 
excreted by the kidneys. If the liver produces too much uric 
acid or the kidneys excrete too little, the patient will have too 
much uric acid in the blood. This condition is called 
hyperuricemia. Supersaturated uric acid in the urine 
(uricosuria) can crystallize to form kidney stones that may 
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block the tubes that lead from the kidneys to the bladder 
(the ureters).(10)  
1.2.4.3. Precautions: 
• Blood test: Patients scheduled for a blood test for uric 
acid should be checked for the following medications: loop 
diuretics (Diamox, Bumex, Edecrin, or Lasix); ethambutol 
(Myambutol); vincristine (Oncovin); pyrazinamide 
(Tebrazid); thiazide diuretics (Naturetin, Hydrex, Diuril, 
Esidrix, HydroDiuril, Aquatensen, Renese, Diurese); 
aspirin (low doses); acetaminophen (Tyienol); ascorbic acid 
(vitamin C preparations); levodopa (Larodopa); or 
phenacetin. These drugs can affect test results. Certain 
foods that are high in purine may increase the patient's 
levels of uric acid. These include kidneys, liver, 
sweetbreads, sardines, anchovies, and meat extracts. 
•  Urine test: Patients should be checked for the following 
medications before the urine test: diuretics, aspirin, 
pyrazinamide (Tebrazid), phenylbutazone, probenecid 
(Benemid), and allopurinol (Lopurin). If the patient needs 
to continue taking these medications, the laboratory 
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should be notified. The laboratory should also be notified 
if the patient has had recent x-ray tests requiring contrast 
dyes. These chemicals increase uric acid levels in urine 
and decrease them in blood. 
1.2.4.4. Description:  
The uric acid blood test is performed on a sample of 
the patient's blood, withdrawn from a vein into a vacuum 
tube. . The urine test requires the patient to collect all urine 
voided over a 24-hour period, with the exception of the very 
first specimen. The patient keeps the specimen container on 
ice or in the refrigerator during the collection period. 
 For the blood sample, the patient should be fasting 
for at least eight hours before the test. The urine test 
requires a 24-hour urine collection. The urine test does not 
require the patient to fast or cut down on fluids. Some 
laboratories encourage patients to drink plenty of fluids 
during the collection period. 
1.2.4.6 Normal results: 
  Reference values for blood uric acid vary from 
laboratory to laboratory but are generally found within the 
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following range: Male: 3.5-7.2 mg/dL; female: 2.6-6.0 
mg/dL. Values may be slightly higher in the elderly. 
  Reference values for 24-hour urinary uric acid vary 
from laboratory to laboratory but are generally found within 
the following range: 250-750 mg/24 hours(10). 
1.2.4.8. Abnormal results: 
The critical value for the blood test is a level of uric 
acid higher than 12 milligrams per deciliter. Increased 
production of uric acid may result from eating foods that are 
high in purine. Increased uric acid levels due to 
overproduction may also be caused by gout, by a genetic 
disorder of purine metabolism, or by metastatic cancer, 
destruction of red blood cells, leukemia, or cancer 
chemotherapy. 
Decreased excretion of uric acid is seen in chronic 
kidney disease, hypothyroidism, toxemia of pregnancy, and 
alcoholism. Patients with gout excrete less than half the uric 
acid in their blood as other persons. Only 10-15% of the 
total cases of hyperuricemia, however, are caused by gout. 
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Abnormally low uric acid levels may indicate that the 
patient is taking allopurinol or probenecid for treatment of 
gout; may be pregnant; or suffers from Wilson's disease or 
Fanconi's syndrome.(10) 
1.2.5. Background Studies:  
Tomoko and Katsugushin, from Jikei University School 
of Medicine, Japan, studied the changes of serum uric acid 
levels (SUA) during normal pregnancy, 10 pregnant women 
studied and their urate metabolism, renal function and 
hormonal changes were evaluated. They found that (SUA) 
was low from the onset of pregnancy to the early phase of 
late pregnancy. (SUA) increased 4 weeks before the deliveries 
and continued to increase after that, but remain within the 
normal range. The production of uric acid reflected by 
urinary uric acid excretion did not change significantly 
through pregnancy and post partum stages.  
Urate clearance changed within the normal range all 
through the course and did not show significant changes. 
Creatinine clearance increased and remained above 100 
ml/min during pregnancy.  
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They concluded that two principle resetting are involved 
in the changes in SUA during normal pregnancy: decrease of 
SUA at the early phase of pregnancy because of a new 
balance of renal function caused by the changes of 
hormones that maintain pregnancy. Slight increases of SUA 
can be explained by increased production of uric acid which 
exceeds the dilution due to enlarged circulating volume, a 
decreasing factor of SUA.(11)        
TThe first report of increased uric acid in preeclampsia 
was by Slemons and Bogerts in 1917.(12)   
Hill LM from Mayo clinic studied the metabolism of uric 
acid in normal pregnancy and toxemic pregnancy, he stated 
that fluctuations in serum uric acid may be as high as 40% 
over a 24-hour period; a single value must be evaluated with 
caution.  
He concluded that alterations in the renal handling of 
uric acid are responsible for the pronounced decrease in 
serum uric acid over the first 20 weeks of gestation, its 
gradual increase in the latter part of pregnancy, and its 
further increase with pregnancy induced hypertension. 
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Although there is a fair degree of overlap between a 
normotensive control and a preeclamptic groups, the level of 
serum uric acid generally correlates with the severity of 
preeclampsia.(12)      
The study conducted by M. Roberts and other at the 
University of Pittsburgh Medical Centre in Pennsylvania is 
one of the most important concerning uric acid in 
preeclampsia. They stated that uric acid is one of the most 
consistent and earliest detectable changes in preeclampsia 
and could be a better predictor of fetal risk than blood 
pressure. (13) 
The investigators examined fetal outcome data from 
972 pregnancies collected from 1997 to 2000 in a nested 
case-control study. The participants were nulliparous and 
had no medical complications pregnancies were grouped in 
eight categories based on the presence or absence of 
combinations of hypertension, hyperuricaemia and 
proteinurea. (13) 
In women with gestational hypertension, hyper-
uricaemia was associated with shorter gestations, smaller 
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birth weight centile and increased risk of preterm birth and 
small-for-gestational age infants. Hyperuricaemia was 
associated with increased risk of these outcomes in the 
presence or absence of proteinuria.  Authors concluded that 
hyperuricaemia is at least as effective as proteinurea at 
identifying gestational hypertensive pregnancies at increased 
risk. (13)  
Ecker, Jeffery et al., measured uric acid levels in blood 
samples from 344 pregnant women including some with 
transient hypertension, chronic hypertension, preeclampsia 
and chronic hypertension and eclampsia. Uric acid levels 
were higher in those with hypertension than those with 
normal blood pressure. Women with chronic hypertension 
and uric acid level of 5.5 mg/dl were 2.5 times more likely to 
develop preeclampsia.(14)   
 Bain Bridge SA and Roberts FM (USA) stated that 
hyperuricaemia is a common finding in preeclamptic 
pregnancies evident from early pregnancy. Despite the fact 
that elevated uric acid often pre-dates the onset of clinical 
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manifestations of preeclampsia, hyperuricaemia is usually 
considered secondary to altered kidney function.  
Hyperuricaemia is associated with adverse fetal 
outcome in hypertensive pregnancies. They hypothesize that 
an elevated concentration of uric acid in preeclamptic 
women is not simply a marker of disease severity but rather 
contributes directly to the pathogenesis of the disorder. Uric 
acid ability to promote inflammation, oxidative stress and 
endothelial dysfunction affects greatly utersplacental 
dysfunction in preeclampsia.(14)     
A study done by Roger A Australia supported strongly 
the work of Ben Bridge and Roberts as it concluded that rise 
is serum uric acid in patients with preeclampsia is 
secondary to placental damage rather than altercating in 
renal function.(15) 
 Bakheit KH (Sudan) studied serum uric acid in patients 
of preeclampsia compared to control group be found that the 
rising level of serum uric acid correlates well with the 
severity of hypertension(19). 
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 Wakwe VC and Abudu O (Nigeria) studied 59 women 
attending antenatal care clinic by measuring plasma uric 
acid and  creatinine clearance.  Results confirmed that 
serum uric acid was able to differentiate between normal 
pregnancy and PIH at P < 0.002.  A further rise in serum 
uric acid in patients of preeclampsia can also predict 
eclampsia. (20)  
 Redman and Bale C (South Africa) studied plasma 
urate and BP in 332 pregnant women with hypertension 
perinatal mortality was markedly increased when maternal 
plasma urate was raised.  They found that maternal 
hypertension even severe without hyperurcaemia  was 
associated with an excellent prognosis for the fetus. 
Conversely when maternal hypertension was mild and 
hyperuricaemia was severe prognosis for the fetus was poor.  
They concluded that in term of fetal death serum urate may 
be more important than blood pressure. (21) 
 Fadil HE, Northship (USA) studied 17 preclampic 
women, 22 hypertensive and 13 normal pregnant women all 
in the 3rd trimester.  Results showed that serum uric acid is 
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elevated, creatinine clearance is impaired and lactate was 
low in preeclampsia than in control group. (22)  
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1.3. JUSTIFICATIONS 
 
1. Preeclampsia is a common problem worldwide and 
Sudan is no exception. So understanding pathogenesis 
and early diagnosis is essential. 
2. Serum uric acid has been reported to be useful in the 
diagnosis of the disease and may reflect the severity of 
the condition. 
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1.4.   OBJECTIVES 
 
1.4.1. General objective:  
To measure serum uric acid level in preeclamptic 
women and  that of healthy pregnant women in Sudan.  
1.4.2. Specific objectives:  
1. To measure the serum uric acid level in patients of 
preeclampsia.  
2. To measure serum uric acid level in healthy 
pregnant Sudanese women.   
3. To detect if there is any significant difference. 
4. To relate serum uric acid results to the severity of 
hypertension . 
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CHAPTER TWO 
2- MATERIALS AND METHODS 
 
2.1 Study design: 
This is a case control  hospital – based, cross-sectional 
study . 
2.2  Study area and duration: 
This study was conducted at obstetrics and 
gynecological department at Khartoum Teaching Hospital. 
Duration of the study was five months. (Sept 2009 – 
Jan 2010) 
2.3  Study population: 
 Pre-eclamptic patients  and healthy pregnant women 
coming from different areas of the Khartoum State. 
Inclusion criteria:  
1-   Pregnant women                           
2-   Gestational age > 28 weeks           
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 3-  Patient diagnosed as preeclampsia based on BP 
>   140 /90 urine protein > ++  dipstick. 
Exclusion criteria:  
The following are excluded :  
1-  known hypertensive before 
2-  known diabetic                        
3-  known renal disease patients.             
4- known  gout patients .                                 
5- Those who received chemotherapy within 4 weeks. 
6- Those on thiazide diuretics .                 
Matching: case and control groups are matched in age, 
gravidity and gestational age . 
2.4  Sampling:  
2.4.1 Case definition: 
Women with preeclampsia attending the obstetrics 
department and who accepted to be included in the study. 
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Control group:  Healthy  pregnant women  who attended 
the obstetrics department and who accepted to be included 
in the study. 
2.4.2  Sample size :   
Fifty patients with preeclampsi and 50 healthy 
pregnant women serving as control group were investigated 
in this study and the sample size was determined according 
to the availability of resources. 
2.4.3  Ethical considerations:  
Verbal consents  from both control and patients were 
obtained after explanation of the purpose of the study . 
2.5  Data Collection Techniques:  
2.5.1 Clinical evaluation: 
2.5.1.1 Clinical history and questionnaire: 
The questionnaire (appendix I) addresses personal data 
of the patient such as name, age, residence, as well as 
clinical information as gravity, gestational age and 
symptoms of preeclampsia. 
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2.5.1.2  Physical examinations:  
Every patient and control were subjected to physical 
examination which included measuring blood pressure, 
assessment of lower limb eodema and fundal level. 
2.5.2 Blood Sample collection:  
From each preeclamptic patient 5 mls of venous 
blood were collected under aseptic conditions into a 
disposable syring. Blood immediately delivered into a plain 
container allowed to completely clot ( about 20 minutes ) 
before being  centrifuged . 
Samples were centrifuged for 2 -3 minutes . 2 mls of 
serum were pipetted into the sample container of the auto –
analyzer, identification of samples was checked throughout 
analytical steps.  
The same steps were applied for the control group. 
2.6  Principle of Methods:  
Automatic analyzer used:  COBAS INTEGRA 400 plus , 
a product  of Roche diagnostics . 
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2.6.1  Product specifications:  
2.6.1.1 System principle:   
Random and continuous access, sample selective 
instrument. 
2.6.1.2 Measurement principles:   
• Absorbance photometry. 
• Fluorescence polarimetry. 
• Turbidimetry. 
• Potentiometry .  
2.6.2 Measurement principle of serum uric acid by 
COBAS INTEGRA: 
Serum uric acid is measured by the absorbance 
photometer module of the autoanalyzer with the following 
properties: 
• Spectrophotometer grating monochromator and 
diode array. 
• Wavelength range 240 – 800 nm, 12 wavelengths. 
• Mono-and bichromatic measurement. 
• Light source: Halogen lamps, 100 W. 
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Analytical method of uric acid: 
Common techniques for measuring uric acid in body 
fluids include:phosphotungstic acid (PTA),uricase and HPLC 
based methods. 
The uricase method is the reference method. Uricase is 
used either as a single step or as the initial step to oxidize 
uric acid. Uricase acts on uric acid to produce allantoin, 
hydrogen peroxide and carbon dioxide. The decrease in 
absorbance as urate is converted is measured with a 
spectrometer at 293 nm. Most current enzymatic assays for 
uric acid involve a peroxidase system coupled with oxygen 
acceptor to produce a chromogen. The difference in 
absorbance before and after incubation with uricase is 
proportional to the uric acid concentration.(23) 
2.6.3    Calibration: 
 The calibration function is the relation between 
instrument signal (y) and concentration of analyte (X) i.e. y = 
f (X).  This relationship is established by measurement of 
samples with known amounts of analyte (calibrators). 
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 The only requirement for calibration is that there 
should be a monotonic relationship between signal and 
analyte concentration over the analytical measurement 
range.  Otherwise the possibility of error occurs. 
 In modern automated autoanalyzer COBAS is not 
exception.  The relationship between analytic concentration 
and signal is often very stable so that calibration is 
infrequent (e.g. at intervals of several months). Calibration 
may be needed before the allowed time e.g. when quality 
control samples is out of the expected range. (23) 
2.7 Quality Control: 
 All patients and controls were interviewed and 
examined by the reseacher.  All tests were run into the 
analyzer by the same operator. 
2.7.1 Quality control of the Auto-analyzer: 
 COBAS INTEGRA 400 plus Quality Control (QC) 
function supports established control rules that can be 
customized to satisfy both local and national QC 
requirements. 
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 It supports all test groups including routine 
chemistries, specific proteins, Therapeutic Drug Monitoring 
(TDM), Drugs of Abuse (DAT), thyroids, and electrolytes.  
There are three control modes, each with its own set of rules. 
Each test can have up to six controls at one time.  Only the 
first three can be used as precision controls. 
 Three modes are recognized: Accuracy, precision, and 
limit. Each is characterized by one or more rules; when the 
rule is broken, a flag is generated on the control result. 
Precision: Checks whether control results have violated rules 
according to the hewhard procedure (commonly known as 
the Westgard rules) or the Rili-RAK precision rules. 
Depending on the rules violated, a systematic or random 
error may have been generated.   
Accuracy: Checks whether control results are within a range 
defined by the assigned value of an assay control and a 
permissible deviation. When control results are out of range, 
a systematic error may have been generate.   Limit:  Checks 
whether control results have exceeded either upper or lower 
limits.  This mode is particularly designed for DAT (16). 
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2.8 Data Analysis: 
 Data obtained from the questionnaire was 
summarized on master sheet. The age, gravidity, blood 
pressure and serum uric acid level of all studied population 
were checked.  
 Preeclamptic patients were categorized into five age 
groups, eight gravidity groups and four blood pressure 
groups. Healthy controls  were categorized into five age 
groups ,eight gravidity groups, blood pressure of control 
group is 120/80.The mean serum uric acid of both case and 
control groups were calculated. The degree of correlation 
(coefficient (r-test) and the probability test (p-value) were 
calculated to show whether there is significance in the 
relationship between blood pressure and mean serum uric 
acid level. 
 Microsoft Excel (Windows 2003, Stata 6.0 for Windows 
98/95/NT and  Statistical Package of Social Sciences  (SPSS) 
version 16 were used for data analysis.  
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CHAPTER THREE 
3- RESULTS 
A total number of fifty Sudanese preeclamptic and fifty 
healthy pregnant women matched in age, gestational age 
and gravity were recruited to this study.  
Both patients and controls were not known to be 
hypertensive ,diabetic, or patients of renal disease,  did not 
received chemotherapy or thiazid dieuretics within 4 weeks 
of the study.   
 The studied population  was divided into 5 age groups 
as follows: 
Eight women (8%) between 21-25 yrs, 22 women (22%), 
between 26-30 yrs, 16 women (16%) between 31 - 35 yrs and 
23 women (23 %) between 36 - 40 years old.  
The studied cases age  distribution was as follows: 
Five women (16%)) less than 21 yrs, 17 women (34%), 
between 21- 25 yrs, 7 women (14%) between 26-30 yrs, 9 
women (18%) between 31- 35 yrs and 12 women (24%) 
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between 36 - 40 years old. (Table 1) 
The healthy controls age  distribution was as follows: 
  Three women (6%) < 21 years, 14 women (28%) 
between 21-25 yrs, 15 women (30%), between 26-30 yrs, 7 
women (14%) between 31 - 35 yrs and 11 women (22%) 
between 36 - 40 years old. (Table 2)  
The gravidity distribution of the studied population was as 
follows: 
Thirty eight women (38%) primigravida,-25 women 
(25%) gravida 2, 16 women (16%), 7 women (7%) gravida 4, 5 
women (5%) gravida 5, 4 women (4%) gravida 6, 4 women 
(4%) gravida 7, and 1 woman (1%) gravida 8. (Table 3)  
Case group  distribution according to gravidity was as 
follows: 
Fourteen women (48%) primigravida, 11 women (25%) 
gravida 2, 8 women (16%) gravida 3,2 women (4%) gravid 4, 
1 woman (2%) gravida 5, 3 women (6%) gravida 6 and 1 
woman (2%) gravida 8. (Table 4)  
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Distribution of control group according to gravidity was as 
follows: 
Twenty eight women (48%) primigravida, 14 women 
(28%) gravida 2, 8 women (16%) gravida 3, 5 women (10%) 
gravid 4, 4 women (8%) gravida 5, 1 woman (2%) gravida 6 
and 4 women (8%) gravid 7. 
 Distribution of case groups according to blood pressure 
was as follows: 
Nineteen women (38%) were 140/90 mmHg, 3 women 
(6%) 140/100 . mmHg, 16 (32%) were 150/100 mmHg and 
12 women (24%) were 160/110 mmHg.  
The control group were normotensive i.e 120/80 
mmHg.  
Mean serum uric acid level  was calculated:  
Case: 50 women; the mean serum uric acid was 7.35 mg/dL.  
Control: 50 women; the mean was 4.47 mg/dL.  
 The mean serum uric acid of both case and control          
was 5.91 mg/dL. (Table 5)   
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Serum uric acid of case gravidity groups was calculated:  
Twenty four women were primigravia; their mean uric 
acid 7.68 mg/dL, 11 women were I gravida II; their mean 
uric acid 6.79 mg/dL, 8 women were gravida III; their mean 
uric acid is 6.95 mg/dL, 2 women were gravida IV; their 
mean uric acid is 7.20 mg/dL, only 1 woman was gravida V;  
her serum uric acid is 6.60 I mg/dL, 3 women were gravid  
VI; their mean uric acid 7.76 mg/dL and one woman were 
gravida VIII; their mean uric acid 6.60 mg/dL.  
The mean of all cases were 7.35 mg/dl   (Table 6) 
The relation between the gravidity and serum uric acid 
in preeclampsia;  P value = .458  is statistically not 
significant.  
Mean serum uric acid of control gravidity groups was 
calculated: 
Fourteen women were primigravias; their mean uric 
acid is 4.38 mg/dL, 14 women were gravid II,   their mean 
uric acid 4.55 mg/dL, 8 women were gravida III; their mean 
uric acid is 4.36 mg/dL, 5 women were gravida IV; their 
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mean uric acid is 4.40 mg/dL, 4 women were gravida V; 
their mean uric acid is 4.70 mg/dL, only one woman was 
gravida VI; her serum uric acid is 5.00 mg/dL and 4 women 
were gravida VII; their mean uric acid 4.42 mg/dL.  
The mean of all cases were 4.47 mg/dL.  (Table 7).  
 Patients of preeclampsia were put into four groups of blood 
pressure and the mean  serum uric acid of each group was 
as follows:  
Nineteen women (38%) were 140/90 mmHg, their mean 
serum uric acid  was 6.45 mg/dL. 3 women (6%) of blood 
pressure 140/100 mmHg. Their mean serum uric acid was 
6.85 mg/dL. 16 women (32%) of blood pressure 150/100 
mmHg; their mean serum uric acid was 7.75 mg/dL.  and 12 
women (24%)  of blood pressure 160/100 mmHg; their mean 
serum uric acid was 8.35 mg/dL. (Figure 1, Table 8). 
,  Statistically probability value and correlation coefficient  
test were calculated to show whether there is significance in 
relationship between blood pressure and serum uric acid 
lvel, they I proved to be highly significant. P value = 0.000. r 
value 0.6. 
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Table 1: Age distribution of case group   
Age (Years)     Frequency Percentage 
  (%) 
          < 21 5 10.0 
21- 25 17 34 
26 - 30 7 14 
   
   
31 - 35 9 18.0 
   
   
36 - 40 12 24 
Total 50 100.0 
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Table (2): Age distribution of control group (n = 50)  
Age (Years)   Frequency Percentage 
   (%) 
       > 21  3 6.0 
 
 
  
21- 25 
 
14 28.0 
 
 
  
 
26 - 30  
 
15 
 
30 
    
31 - 35 
                  
           7 
 
14 
36 - 40  11 22 
 Total  50 100.0 
 
 
  
62 
 
 
 
Table (3): Gravity distribution of case and control  
                                          (n = 100) 
Gravidity  I   Frequency Percentage 
  (%) 
PG I 38 38.0 
 ,   
II 
I
25 25.0 
I
III I 16 16.0 
IV I 7 7.0 
    
V I 5 5.0 
VI 4 4.0 
VII 4 4.0 
-   
VIII     1 1.0 
Total  100 100.0 
 
 
 I    
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Table (4): Gravidity distribution of case 
group  
r r  
 
 
 
   Frequency Percentage 
   (%) 
      
PG 
 
24 48.0 
 
 
  
II 
 
11 22.0 
 
 
  
III 
 
8 16.0 
 
 -. 
 
 
 
 
 
 
  
IV 
 
2 4.0 
V 
 
1 2.0 
 
 
  
VI  3 6.0 
 
VIII  1 2.0 
Total  50 100.0 
 I    
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Table (5): Serum uric acid of control & case group  
                                       
Group n 
 
Mean 
 
   mg/dL 
Case 50  7.35 
    
    
Control 50  4.47 
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Table (6): Serum uric acid of case group  
(n = 50)  
Gravidity (the Frequency Mean 
number of   mg/dL  Pregnancy)   
     
 PG 24 7.68   
     
     
 II 11 6.97 -  
     
 III 8 6.95   
     
 IV 2 7.20   
     
    - 
 V 1 6.6 
 VI 3 7.8 
 VIII 1 6.6 
P value = .458 is not significant
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,  
Table (7): Serum uric acid of control group  
                                (n = 50)  
Gravidity (the Frequency Mean 
 
   
number of  mg/dL 
pregnancy)   
PG 14 4.38 
   
II 14 4.55 
    
III 8 4.36 
   
   
IV 5 4.40 
   
V 4 4.70 
VI 1 5.00 
VII 4 4.42 
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Table (8):  Mean serum uric acid of case group blood 
pressure. 
  Frequency  
Mean serum 
uric acid 
(mg/dL) 
 
Blood 
pressure 
mmHg 
   
     
 140/90 19  6.45 
 140/100 3  6.85   
     
 150/100 16  7.75 
 160/110 12  8.35   
     
-  Total  50   
     
 
 
 P value = 0.000 is significant  
r test = 0.6 is significant 
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CHAPTER FOUR 
4- DISCUSSION 
 
 
The study covered 100 patients 50 case/50 control.    
The study has not considered: residence, tribe, 
education and socio-economic status in the analysis, as 
these factors are more useful in bigger community-based 
studies.  
The age group studied was 20-40 years old, as this age 
is accepted worldwide as safe for conception and most 
preeclampsia incidence is associated with extremities of 
maternal age.  
The study showed greater number of preeclampsia 
around early twenties late thirties and forty this result 
support studies linking extremities of maternal age with 
preeclampsia(1,9).  
  The biggest number of pregnancies was primigravidus 
for both cases  and controls 38%, 5% gravida II, 16% gravida 
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III, 7% gravida IV, 5% gravida V, 4% gravida 6, 4% gravida 
VII and only one percent gravida VIII. 
 This declining percent with greater number of 
pregnancies may  show a tendency of having less children or 
that people prefer family planning.  
Of the high percent of primagravida (38%) women, 
preeclamptic primagravidus were more than healthy 
primigravidus (24 versus I14) this finding is in consistence 
with the studies putting primagravidus as a risk factor (1,5,8,9)    
  There is no relationship between gravidity and serum 
uric acid i.e increased parity is not associated with rise in 
serum uric acid as far as we know no one linked greater 
gravity with the rise in serum uric acid. 
Serum uric acid of the control group of a mean 4.47 
mg/dL is within the normal range (2.6 – 6 mg/dL). This is 
compatible with the scientific fact that normal pregnancy is 
not associated with rise in serum uric acid(l,9).  
Serum uric acid of the case group of a mean of            
7.35 mg/dL is higher than the normal range this is 
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consistent with the results of M Roberts and others in 
Pennsylvania, one of the most important studies about the 
rise of serum uric acid with preeclampsia that study cover 
972 case of preeclampsia and the mean serum uric acid 7.6 
mg/dL this is close to our results(13). 
Ecker and Jeffry et al on their study titled clinical 
utility of serum uric acid measurement in hypertensive 
disease of pregnancy found that precelamptic women with 
serum uric acid of 6.5 mg/dL are 2.5 times more likely to 
develop preeclmpsia(14).  
  Tsukimori,  Yoshitomi, et al  Japan (2008) in their 
study that aim to investigate whether serum uric acid level 
correlate with superoxide generation and oxidative stress in 
preeclampsia(17).  They found that the mean serum uric acid 
is 6.6 + 1.5 mg/dL in preeclampsia compared to normal 
pregnancy of 4.0 + 0.7 mg/dL.  This is also close to our 
control and case groups values.   
S Thangaratinam, Ismail, et al, UK (2006); in their study 
about accuracy of serum uric acid in predicting 
complications of preeclampsia.  Found that serum uric acid 
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greater than or equal to 7.25 mg/dL is highly predictive of 
eclampsia. This value is no far from our findings(18). 
Dividing the  high blood pressure into 4 groups (Table 8 ) 
and relating blood pressure to serum uric acid (Figure 1) 
showed that the higher the Blood pressure the higher the 
level of serum uric acid.  
Probability test done supported this strongly (P = 
0.000).  The relation between the rise in BP and uric acid 
was in consistence with the work done by Eker, Jeffry et 
aI(14).  
Finally Bakheit KH (Sudan) studied serum uric acid in 
preeclampsia compared to control found that the mean 
serum uric acid of control 4.5 mg/dL and that of case group 
6.5 mg/dL; these values are approximate to the results of 
this study . 
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4.1 CONCLUSION 
 
 
According to the results obtained and the discussion; 
conclusions are:  
1. Preeclampsia is associated with rise in serum uric acid 
level.  
2. The higher the blood pressure in preeclampsia the 
higher the rise in serum uric acid level.  
3. Hyperuricaemia in preeclampsia is common in 
primigravidus status. 
4. Increased gravidity is not associated with 
hyperuricaemia. 
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4.1 RECOMMENDATIONS  
  
1. Serum uric acid  measurement should  be included in 
the follow up of preeclampsia.  
2. Serum uric acid level can be  a good predictive factor for 
preeclampsia. 
3. Further studies about uric acid in preeclampsia should 
be conducted. 
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University of Khartoum 
Faculty of Medicine 
Department of Pathology 
Medical & Health Studies Board 
  
Questionnaire 
SERUM URIC ACID IN PATIENTS WITH 
PREECLAMPSIA COMPARED TO CONTROL   
Serial No:………………………..      Date: ………………….. 
1. Name:……………………………………………………………. 
2. Age: …………….. 
3. Residence:………………………………………………………… 
4. Gravidity:………………………………………………………….. 
5. Gestational Age:…………………… 
6. Symptoms  and  history  of  present  disease: 
……………………………………………………….. 
 
7. Physical examination: 
a. BP 
b. Oedema  
8. Results of investigations: 
a. Proteinuria 
b. Serum uric acid 
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